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MerlinAngiomotins were originally identiﬁed as angiostatin binding proteins and implicated in the regu-
lation of endothelial cell migration. Recent studies have shed light on the role of Angiomotins and
other members of the Motin protein family in epithelial cells and in pathways directly linked to the
pathogenesis of cancer. In particular, Motins have been shown to play a role in signaling pathways
regulated by small G-proteins and the Hippo–YAP pathway. In this review the role of the Motin pro-
tein family in these signaling pathways will be described and open questions will be discussed.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. The Angiomotins – Discovery
Sequencing of clones from human brain cDNA libraries identi-
ﬁed a 5061 base pair (bp) cDNA clone, designated KIAA1071, with
an open reading frame (ORF) coding for a 473 amino acid protein
[1]. However, it was not until 2001 through a yeast-two hybrid
screen of a human placenta cDNA library, using the kringle do-
mains 1–4 of angiostatin as bait that Angiomotin, the founding
member of the motin family, was ﬁrst cloned [2]. Northern blot
analysis detected two transcripts at 6.5 kb and 7.5 kb in a broad
spectrum of analyzed tissues. Given the predominant expression
of Angiomotin in endothelial cells and its involvement in mediat-
ing the anti-migratory properties of angiostatin; it was given its
name [2]. With a cytogenetic location at chromosome Xq23, it
shares 85% homology with the mouse Angiomotin ortholog, and
was given the HUGO nomenclature gene designation AMOT.
Angiomotin is a 675 amino acid protein and with an estimated
molecular mass of 80 kDa, it was termed Amot-p80 [2,3].
Subsequent analysis of GenBank databases identiﬁed 2 additional
polypeptides that show signiﬁcant sequence homology to
Amot. These were Angiomotin-like 1 (AmotL1, a.k.a. JEAP) andAngiomotin-like 2 (AmotL2, a.k.a. MASCOT). JEAP (junction-en-
riched and -associated protein) was initially identiﬁed in a screen
for novel tight-junction (TJ)-associated proteins by a ﬂuorescence
localization-based expression cloning method [4] and due to sim-
ilarity to Angiomotin, subsequently named Angiomotin-like 1 [5].
Human AmotL1 (hAmotL1) (NCBI Accession NM_130847) is a
956 amino acid protein with a predicted molecular mass of
approximately 106 kDa. The human AmotL1 (hAmotL1) gene is lo-
cated at chromosome 11q21 and shares 85% sequence homology
with mouse AmotL1 (mAmotL1), an 882 amino acid protein (iso-
form 2, Uniprot database). Angiomotin-like 2 (AmotL2) (NCBI
Accession NM_016201) is a 780 amino acid protein with a pre-
dicted molecular mass of 86 kDa. The gene is mapped to chromo-
some 3q21-q22 [5], and like AmotL1 the coding sequence shares
85% homology with mouse AmotL2, a 772 amino acid protein.
Functional characterization of AmotL2 showed it colocalizes with
MAGI-1 at epithelial tight junctions, an interaction found to be
dependent on the AmotL2 coiled-coil domain. The protein was
therefore named MAGI-1-associated coiled-coil tight junction pro-
tein (MASCOT) [6]. In the interest of simplicity we will subse-
quently refer to these as AmotL1 and AmotL2. Since these
proteins exhibit such signiﬁcant sequence homology, suggestive
of a common evolutionary origin, this family of proteins was
named Motins [5]. Later studies identiﬁed an additional form of
Amot called p130 (Amot-p130), which arises from alternative
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tended 409 amino acid N-terminus [3]. Amot-p130 (NCBI Acces-
sion NM_001113490) is a protein composed of 1084 amino acids
with an estimated molecular mass of 130 kDa. The apparent lack
of proteolytic cleavage sites suggests that Amot-p80 is not gener-
ated from Amot-p130 via hydrolytic catalysis, but that the Amot
gene produces both Amot isoforms through alternative splicing [3].
The Motin protein family members share several structural
characteristics (Fig. 1). The N-terminus, shared between Amot-
p130, AmotL1, and AmotL2, is composed of conserved glutamine-
rich domains, PPxY motifs (Amot: 239PPEY242 and 284PPEY287;
AmotL1: 310PPEY313 and 367PPEY370; AmotL2: 210PPQY213 and the
slightly divergent 252PPVF255), plus a recently identiﬁed unconven-
tional LPTY motif lying upstream of the other two (Amot:
106LPTY109; AmotL1: 188LPTY191; AmotL2: 104LPTY107) [7,8]. Of note,
AmotL2 differs from the other members at one of the PPxY motifs,
as the tyrosine residue is replaced by phenylalanine. Remarkably
these motifs are highly conserved, not only among the Motin fam-
ily members, but also across species [8]. Since Amot-p80 lacks the
entire N-terminal, these motifs are not present. The conserved
coiled-coil (CC) domain and the C-terminal PDZ-binding domain
compose the C-terminal region. The predicted locations for the
coiled-coil domains are as follows: Amot-p130 (429–689 aa;
721–751 aa); AmotL1 (438–639 aa; 665–694 aa; 729–762 aa);
AmotL2 (308–581 aa) (Uniprot database). Importantly, the N-ter-
minal 242 amino acids of Amot-p80 was suggested to encode for
a positively charged CC fold due to its positional conservation with
amphiphysin (bin/amphiphysin/rvs) BAR domain [9,10]. Since this
domain is a conserved region across the Motin family members it
was termed Amot coiled-coil homology (ACCH) domain [11]. The
coiled-coil regions comprise two or more right-handed a-helices
wrapped around each other with a left-handed superhelical twist
[12]. CC domains contribute to several biological and structural
functions, including oligomerization. Oligomeric regulation has
been described for all of the members of the Motin family, either
by forming homo-oligomers through self-association, or hetero-
oligomers with other family members through their CC domains
[6,13,14]. Between the conserved CC domain and the C-terminalAmot-p80
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Fig. 1. The Motin protein family. Angiomotin p80 (Amot-p80) is an N-terminal trunc
Angiomotin-like proteins 1 and 2 (AmotL1 and AmotL2), share sequence identity to Amo
sites with available experimental conﬁrmation. ⁄⁄ depicts ubiquitination sites with a
domain. PDZ – Post synaptic density protein (PSD95), Drosophila disc large (Dlg1) and ZPDZ-binding region is localized an angiostatin-binding hydropho-
bic domain, present in Amot-p80 and Amot-p130, yet absent in
AmotL1 and AmotL2 [2,5]. The consensus motif for the PDZ domain
binding is highly conserved, and its presence in the Motins’ struc-
ture offered the ﬁrst clue for their potential involvement in signal-
ing pathways.
In terms of protein topology, a number of models have been
proposed [3,15,16]. Based on studies in mouse aortic endothelial
(MAE) cells, in which an antibody used against the angiostatin-
binding domain was effective without any prior membrane perme-
abilization step, it was proposed that Angiomotin localizes to the
cell membrane as a transmembrane protein with both isoforms
forming a transmembrane loop, the angiostatin-binding domain
oriented outwards and the N- and C-terminal domains in an intra-
cellular orientation [16]. DNA vaccination of mice, targeting human
Amot-p80, generated antibodies that bind to Amot-p80 on the
endothelial cell surface. These studies further support a topology
where the angiostatin-binding domain is in an extracellular orien-
tation [17,18]. In contrast, in studies with bile canaliculi fractions
prepared from mouse liver without the use of detergent, endoge-
nous Amot-p130, Amot-p80, and AmotL2 were extracted with
intracellular fractions, suggesting that these Motins are not
trans-membrane proteins [2,15]. Interestingly, recent studies dem-
onstrated the exclusive binding of angiostatin to glioblastoma cells
that express Angiomotin. While both proteins appear to be present
on the cell surface they do not appear to colocalize, suggesting
Angiomotin mediates angiostatin binding indirectly.
The structural similarities between the Motins and the absence
of an obvious angiostatin-binding domain in AmotL1 and AmotL2
might suggest that this family of proteins interacts with the
hydrophobic phospholipid membrane bilayer indirectly. Moreover,
protein topology prediction algorithms, such as Topcons [19] also
paint a complex picture predicting the presence of potential hydro-
phobic motifs featuring a transmembrane topology but no pre-
dicted extracellular domains. Thus, further experimental analysis
is needed to clarify these questions.
Although there is a high degree of similarity between the Motin
proteins, there are functional differences that are still not fully675 aa
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ferently expressed across different tissues and, if expressed in the
same tissue, exhibit variable spatiotemporal and expression level
patterns. Analysis of mRNA expression of Amot, AmotL1, and
AmotL2 in diverse human tissues, based on data generated by
the Illumina human BodyMap 2.0 platform, demonstrates that all
family members are expressed in the surveyed tissues, yet at var-
iable expression levels (Fig. 2). Amot showed higher transcript lev-
els in the testis, followed by the brain and thyroid. The lowest
expression is seen in the liver and adrenal gland. AmotL1 is highly
expressed in skeletal muscle, representing the highest mRNA
expression level across the entire analysis. The lowest levels are
found in the blood. AmotL2 expression is highest in breast and
lowest in the liver. This analysis is in agreement with previous
studies examining Motin tissue expression patterns not only in hu-
man but also in mouse. Speciﬁcally, Amot expression was found in
mouse and rat skeletal muscle [5,20], highly expressed in mouse
brain, pancreas, and salivary gland [3,5,15]. Similar to its human
homologue, AmotL1 mRNA was predominantly expressed in
mouse skeletal muscle [5], pancreas, and salivary gland [15]. The
expression pattern of the Motins is therefore tissue-type depen-
dent, predicting functional variability within the family.
The expression patterns of Motin family members are also var-
iable during development. Amot, AmotL1, and AmotL2 mRNAs
showed spatiotemporal-dependent expression in the mouse uterus
during pre-implantation and post-implantation periods [21–23].
At a very early stage of pregnancy, Amot and AmotL1 transcripts
were initially expressed in the luminal epithelium and later on inWhole blood
Whilte blood cells
Lymph node
Spleen
Thymus
Brain
Cortex
Cerebelum
Spinal cord
Heart
Small intestine
Adipocyte
Retina
Smooth muscle
Colon
Skeletal muscle
Pancreas
Kidney
Salivary gland
Liver
Breast
Lung
Thyroid
Adrenal gland
Skin
Ovary
Uterus
Placenta
Prostate
Testis
Cervix
Amot
Bone marrow
0 1 10 100 1000 0 1 10
Fig. 2. RNA expression proﬁles of Motin family members in human tissue. Results are ba
from 16 normal human tissues was sequenced and mapped. Fragments Per Kilobase o
program and expression levels scaled using (100  FKPM)1/2 (http://cufﬂinks.cbcb.umd.
(green), Muscle (yellow), Internal (blue), Secretory (violet), and Reproductive (turquoisethe stroma. Alteration of their expression pattern occurred within
a fairly small timeframe, speciﬁcally at 4 days post-pregnancy. The
same expression shift was observed during the post-implantation
period. Intriguingly, AmotL2 expression was barely detected in
either period except on day 1 of pregnancy [21]. AmotL2 might
therefore represent an evolutionary outlier of the Motin family, a
concept initially proposed following phylogenetic analysis [5].
Finally, while several cell lines have been used in the functional
studies of the Motin family, in many of these the expression of
endogenous Motin family members could not be detected using
currently available antibodies and/or qPCR. In some cases, studies
from different groups report contradictory ﬁndings in the same cell
line, suggesting experimental conditions could signiﬁcantly impact
expression of Motin proteins. Thus, caution should be exercised in
choosing the appropriate cell type and experimental conditions for
analysis. Table 1 summarizes expression of Motin family members
in cell lines based on the published literature.
2. Regulation of the Angiomotins
A key post-transcriptional regulatory mechanism of the Motins
appears to be by alternative splicing. The ﬁrst evidence for the
occurrence of coding sequencing diversity surfaced with the
description of two splice isoforms at the hAmotL1 locus, the ﬁrst
lacking exon 2 and the second exons 2 and 3 [24]. It was predicted
that only the ﬁrst isoform coded for a functional protein of 906
amino acids with a predicted molecular weight of 90 kDa [24]. Uni-
prot protein sequence database predicts two alternative transcriptsAmotL1 AmotL2
100 1000 0 1 10 100 1000
sed on data generated by the Illumina human BodyMap 2.0 platform. RNA obtained
f exon per Million fragments mapped (FPKM) were calculated using the Cufﬂinks
edu/). Major tissues are colored according to 6 categories: Immune (red), Nervous
).
Table 1
Expression levels of Motin family members in different cell lines.
Cell lines Amot-p130 AmotL1 AmotL2 Analytic methodology Ref.
Epithelial
ACHN   Unknown WB [47]
BT474 +/  Unknown WB [46,48]
BT549  Unknown WB [48]
HCC1937 + Unknown Unknown WB [46]
HEK293 + +/ +/ WB/qPCR [47,48]
HEK293T + – +/ WB/qPCR [46,47]
HeLa   + WB/qPCR [47]
HEpG2   Unknown WB [48]
Hs-578T +/  Unknown WB [46,48]
H2.35  + Unknown WB [47]
MCF7 +/  Unknown WB [46,48]
MCF10A –  + WB/qPCR [46–48]
MDA-MB-231 +/  Unknown WB [46,48]
MDA-MB-436 + Unknown Unknown WB [46]
MDA-MB-468 + Unknown Unknown WB [46]
MDCK +/  + WB/qPCR [9,46,47]
SK-Br3 +/  Unknown WB [46,48]
T47D +/  Unknown WB [46,48]
ZR75 + Unknown Unknown WB [46]
Endothelial
BCE +  Unknown WB [13]
HUVEC  + Unknown WB [13]
MAE  + Unknown WB [13]
MS-1 + + Unknown WB [13]
Pmt-EC + + Unknown WB [13]
TEC + + Unknown WB [13]
Fibroblast/Fibroblast-like
Cos-7   + WB/qPCR [46]
MEF + + Unknown WB [46]
NIH-3T3  + + WB/qPCR [46]
Neural
SC4 + Unknown Unknown WB [7]
RT4 + Unknown Unknown WB [7]
R3 + Unknown Unknown WB [7]
MPNST 90-8TL + Unknown Unknown WB [7]
The endogenous expression of the Motins is based on studies that speciﬁcally screened for Motin expression across various cell lines. Motins are showed solely as present or
absent in the respective cell line regardless of their expression levels. () Absent. (+) Present. (+/) Inconsistent data between detection approaches. Unknown indicates that
the expression of the Motin family member has not been tested in that particular cell line. WB – Western blotting. qPCR – quantitative PCR.
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106 kDa protein, and a second one generated by a 50 amino acid
deletion on AmotL1 N-terminal with a molecular mass around
101 kDa. Regarding Amot, several studies have broadly character-
ized the two known splice isoforms, Amot-p80 and Amot-p130.
As previously stated, Amot-p130 carries an extended N-terminal
of 409 amino acids and this is the only structural difference from
Amot-p80 [3]. The N-terminal region alone is sufﬁcient to generate
temporal, spatial, and functional differences between isoforms
[3,9,14,20,25]. Even though Amot has only two transcript variants
described so far, additional bands corresponding to proteins of 70
and 110 kDa were observed in Western blotting experiments by
different groups [14,20,26]. Whether these bands represent func-
tional or a transient unknown Amot isoforms remains to be deter-
mined. To the best of our knowledge, besides the 780 amino acid
protein [5], the only alternative splicing event described for the hA-
motL2 locus is a 466 amino acid form lacking the 313 amino acids
located on the N-terminal of AmotL2 [24,27]. Although the molec-
ular mass of this short isoform is not mentioned in the study [27],
commercial antibodies developed against AmotL2 detect a 51 kDa
protein that potentially represents this isoform (Sigma–Aldrich;
GenWay Biotech; AvivaSystemsBiology; and others). Uniprot fur-
ther predicts three additional human isoforms, two of which have
no available experimental conﬁrmation. Speciﬁcally, a 779 amino
acid peptide with predicted molecular mass of 85 kDa; a 777 ami-
no acid protein generated by a two residue deletion at positions
525–526 (encodes a protein with predicted molecular mass of
85 kDa); and ﬁnally a 837 amino acid protein generated by a 58amino acid insertion, starting at the N-terminus, predicted to en-
code a 92 kDa protein. In mice, multiple transcript variants of the
Motin family are predicted and we refer to the available databases
for further analysis.
Other mechanisms involved in the regulation of the Angiomo-
tins have only recently begun to come to light. Previous omics-type
approaches identiﬁed a multitude of post-translational modiﬁca-
tions of the Motin proteins, including phosphorylation, ubiquitina-
tion, acetylation, and glycosylation. In some cases, the Motins were
identiﬁed as substrates for speciﬁc enzymes, such as the ataxia tel-
angiectasia mutase (ATM), ataxia telangiectasia and Rad3-related
(ATR) or cyclin-dependent kinase 2 (CDK2) kinases [28,29]. How-
ever, these ﬁndings remain to be conﬁrmed and have not been
studied in depth. There are several phosphorylation sites predicted
by the PhosphoSite database within the Motin family. Multiple hits
were suggested and, for simpliﬁcation, we will only discuss the
sites conﬁrmed experimentally. Lists of potential phosphorylation
and ubiquitination sites (predicted by UbPred database) in human
Motins are detailed in Table 2.
The post-translational modiﬁcations that have been studied in
more detail are the ubiquitination at Lysine 481 and phosphoryla-
tion of Angiomotin p130 at serine 175. In HEK293T cells, Amot-
p130 is ubiquitinated at residue Lys481 by Atrophin-1 interacting
protein 4 (AIP4)/Itch, a member of the Nedd4 (neural-precursors-
cell-expressed developmentally down-regulated)-like ubiquitin
E3 ligases family. AIP4 ligase activity is triggered by direct interac-
tion between AIP4 WW1 and WW2 domains and Amot-p130 PPxY
motifs, which promotes either self or Amot-p130 ubiquitination
Table 2
Potential Phosphorylation and Ubiquitination sites in human Motin family members.
Amot-p130 AmotL1 AmotL2
Tyr109 Ser787 Tyr191 Ser724 Thr10 Tyr573
Ser175 Tyr836 Tyr218 Ser793 Tyr92 Thr596
Ser305 Tyr842 Tyr219 Ser796 Lys100 Ser608
Ser312 Tyr847 Ser225 Thr803 Tyr107 Ser609
Tyr420 Thr848 Ser241 Ser805 Ser159 Ser661
Phosphorylation sites Tyr527 Ser852 Ser262 Ser809 Ser183 Ser753
Tyr599 Ser855 Ser269 Ser828 Ser236 Ser759
Ser712 Ser1059 Ser295 Ser900 Lys408 Ser762
Ser714 Thr1061 Thr373 Thr901 Ser540
Ser718 Ser374 Ser906
Tyr661 Ser924
Ser720
Lys94 Lys520 Lys174 Lys326 Lys100
Lys156 Lys525 Lys195 Lys649 Lys111
Lys209 Lys535 Lys246 Lys881 Lys436
Ubiquitination sites Lys219 Lys545 Lys254 Lys929 Lys721
Lys231 Lys553 Lys302 Lys943
Lys255 Lys619
Lys481
The phosphorylation and ubiquitination sites displayed are based on predictions made by Phosphosite and UbPred databases.
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(LATS)1/2, a core component of the Hippo signaling pathway that
also binds AIP4 [30]. Amot-p130 is thus a physiological substrate
for the E3 ligase, a role extended to AmotL1 but not to AmotL2
or Amot-p80 [30]. Other members of the E3 ubiquitin ligase family,
Nedd4 and Nedd4.2, also induced Amot-p130 and AmotL1 poly-
ubiquitination and proteasome-dependent degradation. However,
phosphorylation of Nedd4.2 by the non-receptor tyrosine kinase
c-Abl was shown to inhibit AmotL1 degradation [31]. Recruitment
of c-Abl is promoted by yes-associate protein (YAP), a transcrip-
tional co-factor involved in Hpo–YAP signaling. It was found that
YAP promotes Nedd4.2 phosphorylation by c-Abl, thus ensuring
Nedd4.2 does not target AmotL1 for 26S proteasomal degradation
[31]. Furthermore, through its WW domains, Nedd4 binds to
Amot-p130 ﬁrst and second L/PPXY motifs, akin to the YAP-
Amot-p130 association. This suggests that YAP might compete
with Nedd4 for Amot-p130 binding [8]. Whether YAP, by binding
to Amot-p130, prevents its Nedd4 ubiquitin-dependent degrada-
tion is unknown and further studies are needed to address this
question. Importantly, both direct (BT474, HEK293T, and MCF7 cell
lines) and indirect (in MDA-MB-468 cells) correlations between
AIP4 activity and Amot-p130 steady state levels were found to be
cell-context dependent [8,30].
Experimental conﬁrmation of Motin family member phosphor-
ylation was recently reported by multiple groups who identiﬁed
LATS1/2-dependent phosphorylation of Amot-p130(Ser175),
AmotL1(Ser262), and AmotL2(Ser159) at conserved HVRSLS mo-
tifs [23,30,32,33]. LATS2 binds AmotL2 on its N-terminal 307
amino acids [34], and Amot-p130. The direct binding between
LATS2 and Amot was enhanced by Amot Ser175 phosphorylation
and is dependent on LATS kinase activity [23,33]. The phosphor-
ylation of Motins by LATS has been shown to occur both in vitro
and in vivo [23,30,32,33]. Finally, a model was proposed where
both phosphorylation of Amot-p130 at serine 175 and ubiquitina-
tion at Lysine 481 act together as a major regulatory mechanism
to mediate YAP activity and Hpo–YAP pathway signaling [30].
Under serum starvation conditions, activation of the Hippo path-
way triggers Amot-p130 phosphorylation by LATS1/2 at Ser175.
AIP4 binding to phosphorylated Amot-p130 impedes the AIP4–
LATS1/2 interaction and subsequent LATS degradation. Once asso-
ciated, Amot-p130 is ubiquitinated by AIP4 at Lys481 increasing
its steady state levels. The increased levels of LATS and Amot-
p130 promote YAP ubiquitination [30]. The regulation of YAPby Amot-p130 is still not fully elucidated and will be discussed
further below.
3. Functional redundancy in the Motin family
The extent of functional and genetic redundancy between the
members of the Motin family is unknown. As discussed above, Mo-
tin expression patterns suggest both distinct and overlapping roles,
however limited functional evidence exists so far. In the mouse
embryo (zygote), simultaneous silencing of Amot/AmotL1/AmotL2
resulted in a remarkable increase in cells expressing the differenti-
ation gene Cdx2+ compared to depletion of Amot alone. Thus genet-
ic redundancy between the Motin family appears to occur in
promotion of embryonic inner cell mass (ICM) differentiation
[22]. Furthermore, simultaneous knockdown of the Motin proteins
in HEK293T cells caused a striking up-regulation in the activity of a
Wnt reporter when compared to knocking down each member
alone, which resulted in the down-regulation of the Wnt signaling
[27]. Together with other studies [8], these ﬁndings present initial
evidence for the occurrence of both genetic and functional redun-
dancy within the Motin family.
4. Function: role in endothelial cell biology and angiogenesis
Given that the Angiomotins were originally discovered as medi-
ators of endothelial cell migration, early studies into the role of the
Motin family during development focused on endothelial cells (EC)
biology and blood vessel formation. Given the focus of this review,
we will only cover these studies brieﬂy.
Studies to examine the role of Motin family members in vivo
have suggested these proteins have critical functions during devel-
opment. Amot knockout 129/SvEv background mice displayed
early lethality and most mice died soon after gastrulation due to
defects in cell migration [35]. The severity of this phenotype is
dependent on genetic background, as crossing the Amot+/ 129/
SvEv mice to C57/B6 to generate a mixed 129/B6 background re-
sulted in a delayed lethality of the Amot/mice (75% die between
E11 and E15). Careful analysis of these mice indicated that Amot
plays a critical role in blood vessel formation through regulation
of endothelial cell migration and polarity. Similarly, the knockout
of Amot in Zebraﬁsh embryo also impaired endothelial cell migra-
tion and blood vessel formation [36]. Efforts to manipulate the
expression of other members of the Motin family have also been
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phenotype similar to Amot knockdown with a migratory defect of
endothelial cells and vessel formation, although the mechanisms
might differ [13]. Concerning AmotL2, knockdown in Zebraﬁsh em-
bryos resulted in cell migration and proliferation defects [37,38].
Overall, the effect of knocking down either one or several members
of the Motin family leads to defective phenotypes such as impaired
EC migration, polarization, and proliferation.
The regulation of endothelial cell migration and proliferation by
Angiomotins requires their C-terminal PDZ-binding domains. Dele-
tion of those amino acids in AmotL2/Amot-p80 knockdown Zebra-
ﬁsh embryos was sufﬁcient to restrict migration [38,39]. In
mouse embryos, the deletion of Amot PDZ-binding domain under
the EC-speciﬁc Tie promoter inhibited the response of MAE cells
to chemotactic cues resulting in lethality by day E9.5 [25]. Mecha-
nistic studies show that Amot, by binding the polarity complex
Patj/Mupp1:Pals1, indirectly associates with Syx, a RhoA GTPase
exchange factor (RhoGEF) binding-domain protein, forming a ter-
nary complex [39,40]. Speciﬁcally, Amot directly binds to the
PDZ3 domain of Patj/Mupp1, whilst Syx mostly interacts with
Patj/Mupp1 PDZ10 domain. AmotL1 and AmotL2 also associate
with Patj/Mupp1 via its PDZ1 and PDZ2 domains, respectively
[15,39]. Importantly, Amot was shown to strongly associate with
monophosphorylated phosphatidylinositols PI(4)P and PI(3)P
[11]. Thus, it is suggested that Amot, by interacting through its
PDZ-binding domain with Patj/Mupp1:Syx polarity complex, medi-
ates its trafﬁcking through endocytic vesicles from EC junctions to
the leading edge of endothelial migrating EC resulting in
recruitment of Syx activity to the leading edge. The targeting of
the endocytic vesicles is likely mediated by Amot ACCH domain
(lipid-binding domain) [39,41].
5. Function: role in small G-protein signaling
Since Motins have pivotal functions during development, EC
migration and proliferation, additional studies probed whether
epithelial cell polarity is regulated by Amot. Interestingly, all mem-
bers of the Motin family have been shown to associate with tight
junctions through binding to the tight junction-associated proteins
Patj and Pals1 [9,15,39]. Patj and Pals1 are cytoplasmic scaffolding
proteins that together with the transmembrane protein CRB3 form
the apical CRB complex [42]. Work conducted by us and by others
showed that in mammalian epithelial cells, Amot interacts with
Rich1, a Cdc42/Rac1 GTPase Activating Protein (GAP), via their mu-
tual BAR/CC domains [9,43]. This association targets Amot to the
TJs, wherein by binding Patj, Amot forms a complex composed
by Amot:Patj:Pals1:Rich1 localized at the apical membrane. Impor-
tantly, Amot negatively regulates Rich1 GAP activity, which has
been suggested to impair TJ integrity [9]. In addition, Amot directly
binds to Merlin, a negative mediator of Rac1-signaling, also
through their mutual BAR/CC domains [43]. Thus a model emerges
in which Amot plays a role in mediating Rac1 signaling at junc-
tional structures as Merlin and Rich1 compete for Amot binding.
Merlin, by releasing Rich1 from the Amot inhibitory complex,
facilitates Rich1 GAP activity of Rac1 and subsequent signal trans-
duction through direct downstream effectors such as the p21-acti-
vated kinases and MAPK pathway (Fig. 3) [43]. This coordination
was also observed in the pathological setting of neuroﬁbromatosis
type 2 (NF2), a condition caused by the loss of the NF2 gene, which
codes the Merlin protein [44,45]. Amot knockdown in Nf2/ Schw-
ann cells inhibits proliferation in vitro and leads to impaired tumor
formation in vivo [43]. Other studies have also reported positive
regulation of the ERK/MAPK pathway by Amot and AmotL2 in dif-
ferent cell contexts such as Zebraﬁsh embryos, angiogenic endo-
thelial cells (HUVEC) [37], or epithelial breast cancer cell lineslike MCF7, SKBR3 or MDA-MB-468 [46]. Conversely, knockdown
of AmotL2, but not AmotL1, in MCF10A cells activated both AKT
and ERK/MAPK pathways, suggestive of a negative, rather than po-
sitive, mediation of these pro-proliferation pathways [37]. The dif-
ferences in consequences of AmotL2 knockdown could be
attributed to cell-type speciﬁcity. As AmotL2 mRNA and protein
levels are barely detectable in MCF10A cells [47,48] (Table 1), fur-
ther studies are needed to gain a clear understanding of AmotL2
function in these cells.
6. Function: Angiomotin regulation of Hpo/YAP signaling
The Hpo/YAP pathway has been described in a number of recent
reviews [49–51]. Brieﬂy, this pathway was initially characterized
in ﬂies and is highly conserved in mammalian cells. It plays a cen-
tral role in various cellular behaviors including proliferation, sur-
vival, and cell contact inhibition [52–54]. The pathway is
composed of a core kinase cascade, in which the Mst1/2 kinases
(Hippo in ﬂies), in complex with scaffold protein WW45 (Salvador
in ﬂies), phosphorylate LATS1/2 (Warts in ﬂies) and Mob1 (Mats in
ﬂies). Phosphorylated LATS1/2 binds to and further activates the
Mob1 kinase, which in turn, phosphorylates YAP (Yorkie in ﬂies),
a transcriptional co-activator. The phosphorylation of YAP prevents
it from entering into the nucleus, where it can form transcription-
ally active complexes with TEAD (Scalloped in ﬂies) and other tran-
scription factors to drive the expression of pro-proliferative or anti-
apoptotic genes. A series of studies have demonstrated that akin to
what has been observed in ﬂies, the mammalian Hpo–YAP path-
way can also regulate organ size. For example, inducible overex-
pression of YAP in adult mouse liver results in rapid increase in
liver size [55,56]. Comparable hepatomegaly phenotypes were ob-
served when Mst1, Mst2, and WW45 were ablated speciﬁcally in
the liver [57–59]. Finally, increased YAP activity appears to be a
common occurrence in human hepatocellular carcinoma [36].
Recently there has been a ﬂurry of reports implicating Motin
family members in the regulation of the Hpo/YAP signaling in
mammalian cells. The Drosophila Hippo signaling cascade is highly
conserved throughout evolution, and functional conservation was
conﬁrmed in many cases by the ability of mammalian orthologs
to rescue the corresponding Drosophila mutants in vivo [60,61],
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Motin family members do not appear to have Drosophila orthologs
[63]. The protein Expanded (Ex), which shares signiﬁcant sequence
homology to both Amot-p130 and to FRMD6/Willin, was proposed
to represent a functional equivalent in Drosophila [62,64,65]. Ex
PPXY motifs directly interact with Yorkie (Yki) WW domains form-
ing a complex localized at the apical junctions of cells in the eye
imaginal disc [66–68]. This mechanism of interaction, as discussed
below, resembles the physical association between Amot and
AmotL1 with YAP and TAZ. However, FRMD6/Willin alone was
not able to rescue Ex loss in Drosophila [62], thus raising the possi-
bility that Ex function has been split during evolution into the
cooperative actions of Angiomotins and FRMD6/Willin.
Elegant work conducted by Sowa et al. (2009) ﬁrst described
Amot as a YAP binding partner. This ﬁnding was part of a global
proteomic survey analyzing de-ubiquitinating enzymes and their
interacting protein complexes in a mammalian cell system [69].
Several studies have subsequently demonstrated that Amot-p130
and AmotL1 directly interact with YAP via Motins LPTY and
ﬁrst PPEY motif (Amot-p130: 106LPTY109 239PPEY242; AmotL1:
188LPTY191 310PPEY313), and mostly the ﬁrst WW domain of YAP
(localized between 171 and 208 residues of YAP [70]. This binding
is independent of their second PPEY motif and PDZ-binding do-
main as mutations in these regions showed only mild effects
[7,31,37,47,48,71]. Yet considerable decrease in the Amot–YAP
interaction was observed with Amot coiled-coil (CC) domain mu-
tants [47]. Regarding AmotL2, its PPXY motif (210PPEY213) was
shown to bind YAP mainly through the ﬁrst WW domain, and inde-
pendently of the PDZ-binding motif [34,37]. Noteworthy, the asso-
ciation of Amot-p130, AmotL1, and AmotL2 to TAZ (YAP1 paralog)
occurs exclusively via the Motin PPXY motif and TAZ WW domain
[48,72]. Consistently, neither YAP nor TAZ show interaction with
the short isoform Amot-p80. Therefore, at least under the condi-
tions used in the above-mentioned analyses, the Motin family
members represent a strong binding partner of YAP. Interestingly,
several other proteins including LATS1/2 also bind to the WW do-
mains of YAP through their PPXY motifs [73–78].
It should be noted that some potential discrepancies exist in
the literature as to which isoform of YAP interacts with the Mo-
tins. Some studies have shown that the Motin family members
bind YAP isoform 2, which has two WW domains, but not to iso-
form 1, with one WW domain [30,71,79]. The difference between
the two isoforms consists of an extra 38 amino acids that com-
pose the second WW domain. Intriguingly, a number of other
studies have identiﬁed an interaction between Motins and the
YAP1 isoform. These differences could result from multiple rea-
sons such as different experimental systems or protein expression
beyond physiological levels. In any case, caution is advised when
determining which YAP isoform is being used in a given experi-
mental setup. Indeed, at least two out of the eight YAP isoforms
appear to differently regulate the Hpo/YAP signaling pathway
[71,74].
Besides YAP, the Motins also associate with other effectors of
the Hpo/YAP signaling pathway. Speciﬁcally, Merlin interacts with
Amot-p130 through their mutual CC domains [43]; LATS2 associ-
ates with Amot-p130 CC domain, and with the N-terminal 307
amino acids of AmotL2 through its kinase domain, including the
adjacent Mob-1 binding region [23,34]. AmotL2 also binds MST2,
yet the domains involved in this interaction are currently unknown
[34]. KIBRA, an upstream component of the pathway, binds to the
second 284PPEY287 motif of Amot-p130 through its N-terminus
[23]. Whether KIBRA mediates Motin function is not known, yet
this protein is involved not only in regulation of the Hpo–YAP
pathway [80–82] but also in the regulation of epithelial cell polar-
ity [83–85]. Future analyses will help to clarify the signiﬁcance of
this interaction.A number of recent studies have described the negative regula-
tion of YAP by members of the Motin family [33,34,37,47,48,72]
(Fig. 4). Regarding YAP/TAZ subcellular localization, it has been
suggested that upon ectopic expression of Angiomotins in HeLa
and MCF7 cells, YAP and TAZ translocate from the nucleus to the
cytoplasm and in MCF10A cells, Amot-p130 co-localized with the
actin cytoskeleton [37,47,48]. Interestingly, the expression of exog-
enous Angiomotins in some of these systems resulted in the local-
ization to cytoplasmic puncta instead of targeting to TJs [47].
Furthermore, in the tight junction-forming MDCK cells,
Amot-p130 expression induced partial translocation of YAP to
the cytoplasm and co-localization with the TJ protein ZO-1 [47].
Loss-of-function analysis in cell lines expressing at least one of
the three members of the family added further insights into Motins
involvement in the negative regulation of YAP function. Consistent
with ﬁndings from overexpression studies in MDCK or MCF10A
cells, the knockdown of either Amot-p130 or AmotL2 not only
caused loss of TJs with augmented localization of YAP and TAZ in
the nucleus, but also promotion of Epithelial–Mesenchymal Transi-
tion (EMT) and up-regulation of YAP downstream target genes
CTGF and Cyr61 [34,37,47,48]. Noteworthy, attenuation of AmotL1
expression was refractory to these phenotypic and transcriptional
changes, pointing out the distinct behaviors between Motin family
members. Interestingly, in H441 human lung cancer cells, AmotL2
induced a robust shuttling of TAZ from the nucleus to the cyto-
plasm [72]. This highlights cell-context dependency, suggesting
the tissue or organs wherein they are expressed determines Motin
functions (Fig. 2).
Models for the negative regulation of YAP/TAZ activity by the
Angiomotins suggest a number of possibilities leading to localiza-
tion of YAP/TAZ to the cytoplasm/cell junctions. As discussed pre-
viously, a major mechanism of YAP/TAZ regulation is through
exclusion from the nucleus. This is regulated to a signiﬁcant extent
through YAP and TAZ phosphorylation sites Ser127 and Ser89 res-
idues, respectively, leading to cytoplasmic sequestration through
14-3-3 binding [54,86]. Both YAP and TAZ are kinase substrates
of LATS1/2 [76,54]. Once activated, LATS1/2 phosphorylates YAP
on ﬁve HxRxxS consensus sites – Ser61, Ser109, S127, S164, and
Ser381 [87], and TAZ on four HxRxxS motifs – Ser66, Ser89, S117,
and Ser311 [88]. Phosphorylation of YAP Ser127 and Ser381 resi-
dues by LATS1/2 are key events for its inhibition [87] whilst on
TAZ, phosphorylation of Ser89 and Ser311 sites were shown to in-
hibit its transcriptional activity [88].
Accordingly, it has been suggested that Motins serve as a scaf-
fold for Hippo pathway kinases and YAP at TJs, leading to activation
of LATS2 and phosphorylation of YAP2 (Fig. 4) [34]. Yet other stud-
ies show only mild up-regulation of phosphorylated YAP in
HEK293 cells upon exogenous expression of AmotL2 [47]. Other
models suggest that Motin-mediated localization of YAP/TAZ to
the cytoplasm/cell junctions is independent of YAP/TAZ phosphor-
ylation by LATS1/2 [47]. This is supported by studies showing that
this localization it is still observed with YAPS127A and TAZS89A mu-
tants (Fig. 4) [37,48].
In contrast to the ﬁndings ascribing a YAP-inhibitory role for
Angiomotins, we have recently found that Amot-p130 is required
for YAP function both in vivo and in vitro. By using both gain-
and loss-of-function approaches, we ﬁnd that in multiple cell types
Amot-p130 directly interacts with YAP and functions as a positive
regulator by antagonizing YAP interaction with LATS1, promoting
YAP dephosphorylation and translocation to the nucleus (Fig. 4)
[7]. The differences between the observations described above
might reﬂect use of different cell lines or experimental setups.
For example, a potential caveat is the expression of exogenous
Motin family proteins tagged at their C-terminal PDZ binding
domain, which might mask interactions with binding partners
such as Patj/Mupp1. Yet another possibility is that previously
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lating the function of Motin family members. Interestingly, recent
studies suggest that Motin-YAP association might also be regulated
by phosphorylation of the Motins by LATS1/2 (Fig. 4). These studies
show that phosphorylation regulates Motin subcellular localization
and activities related to cell proliferation and migration
[23,30,32,33]. Whether this phosphorylation induces translocation
of YAP/TAZ from the nucleus to the cytoplasm and subsequent
localization to TJs remains to be determined.
Finally, in addition to mechanisms involving the sequestration
of Yap out of the nucleus, we have recently identiﬁed a nuclear
function for Amot-p130 in regulating YAP activity [7]. Amot-
p130 was found in the nucleus where it forms a complex with
YAP and the DNA-binding transcriptional factor TEAD1. Gene
expression proﬁling further supported these ﬁndings and demon-
strates a strong concordance between Amot-p130 and YAP tran-
scriptional proﬁles, suggesting functional cooperation. In fact,
microarray analysis and gene set enrichment analysis (GSEA) indi-
cated that 99.5% of the genes co-regulated by Amot-p130 and YAP
are regulated in the same direction, with signiﬁcant correlation be-
tween the top-ranked Amot-p130 and YAP-regulated genes. Lucif-
erase assays and Chromatin immunoprecipitation (ChIP) coupled
to RT-PCR show that in HEK293 cells, knockdown of Amot-p130
expression inhibited the binding of a YAPS112A mutant to the pro-
moter of ApoE (which encodes Apolipoprotein E). Surprisingly,
binding of YAPS112A to the CTGF promoter was not affected by
Amot-p130 knockdown. Sequential ChIP analysis further corrobo-
rated that Amot-p130 functions as a co-factor in a transcriptionally
active YAP-TEAD1 complex, involved in recruiting the complex to
promoters of a subset of YAP-regulated genes, which does not in-
clude CTGF [7,89].7. Function: Angiomotin involvement in the pathological
setting
The relationship of Angiomotins to the pathogenesis and pro-
gression of human diseases is still poorly understood. The majority
of investigations have centered upon the expression of Amot in a
variety of cancers and its role in modulating angiogenesis, an
essential process for cancer progression and survival. A mouse
model of hemangioendothelioma that overexpresses Amot-p80 re-
sulted in fast-growing invasive tumors that were larger than con-
trols [90]. In contrast, an Amot mutant-expressing cell line in
which the C-terminus PDZ-binding motif was deleted produced
smaller, dormant tumors that displayed a high level of apoptosis.
The Amot mutant tumors remained dormant for more than 21 days
and did not invade surrounding tissues. Both Amot and deletion
mutant tumors were vascularized, but the deletion of the C-termi-
nal amino acids resulted in inhibited cell migration, suggested as
an explanation for the lack of invasiveness [90].
Subsequent screening of human breast tumors has revealed sig-
niﬁcantly increased expression of Amot in tumors relative to nor-
mal tissue [91]. In contrast, AmotL1 and AmotL2 have shown no
signiﬁcant correlation with tumor burden. Furthermore, Amot
overexpression correlated with tumor grade, decreased survival,
and metastatic disease. Taken together, these ﬁndings imply an
important role for Amot in the context of tumor progression and
underscore the suitability of Amot as a potential biomarker and a
target for anticancer therapeutics.
Efforts thus far to design Amot-based therapies have centered
on immunological-based strategies. A DNA-based vaccine against
human Amot-p80 produced in mice has shown promising results
in a mouse model of breast carcinoma [18]. Implantation of mouse
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growing tumors in mice vaccinated with empty vector. By contrast,
vaccination with Amot-p80 inhibited tumor growth completely in
the majority of mice. In the few examples where tumors did devel-
op the tumors grew much slower compared to control mice. The
signiﬁcant suppression of TUBO tumor growth in response to
Amot-p80 vaccination was partially abrogated in CD4-depleted
mice and completely nulliﬁed in B cell knockout mice, suggesting
vaccination effects are antibody-dependent. Amot-p80 vaccination
was also tested using a more aggressive transgenic breast cancer
model, based on Her-2/neu oncogene under the control of the
mouse mammary tumor virus promoter (MMTV). Vaccination with
Amot-p80 slightly delayed tumor progression, but when combined
with vaccination against Her-2 extracellular and transmembrane
domains, a synergistic effect was observed and 80% of vaccinated
mice survived for more than 70 weeks, compared to the complete
lethality at 20 and 25 weeks for control and Amot-alone vaccina-
tion, respectively [18,92]. Signiﬁcantly, the expression of Amot
was observed to increase with the progression of neoplastic lesions
to invasive carcinomas [92]. Vaccination with Amot-p80 inhibited
angiogenesis in implanted tumors, and isolated Amot antibodies
inhibited the migration of mouse aortic endothelial cells, replicat-
ing the effects of angiostatin. Finally, Amot-p80 vaccination re-
sulted in increased permeability of TUBO tumors, which
increased the efﬁcacy of chemotherapy [92].
Interestingly, Amot expression is found to be signiﬁcantly
upregulated in schwannomas from NF2 patients, which displayed
a primarily localization of Amot to the nucleus [7]. Further analysis
of a role for Amot in this tumor type found that Amot is essential
for the development of schwannomas by Nf2-null Schwann cells
[43]. Using an orthotopic model of NF2-associated schwannoma,
luciferase-expressing Nf2-null schwann cells (SC4) that stably ex-
press Amot shRNA were implanted intraneurally into the sciatic
nerve and tumor progression was monitored via bioluminescent
imaging. In contrast to control SC4 cells, which formed substantial
tumors one week after implantation, Amot knockdown resulted in
a signiﬁcant impairment in the growth of schwannomas. Western
blotting revealed sustained suppression of Amot expression and
MAPK signaling, which explains the slower tumor growth and is
consistent with the proposed mechanism. Together, these results
demonstrate the requirement of Amot for development of schwan-
noma in response to loss of Nf2.
Further highlighting the interplay between Nf2, Amot and the
Hpo–YAP pathway in pathological scenarios in vivo is the ﬁnding
that Amot-p130 enhanced the activity of Yap to promote tissue re-
pair and liver tumorigenesis [7]. Amot conditional knockout (KO)
mice were crossed with albumin-Cre transgenic mice generating
a mixed AmotKO (Alb-cre:Amotﬂox/ﬂox) genetic background with li-
ver-speciﬁc deletion of Amot. After 3,5-diethoxycarbonyl-1,4-dihy-
drocollidine (DCC)-induced injury, it was observed that in response
to injury the proliferation of biliary epithelial cells (BEC) was im-
paired in the Alb-cre:Amotﬂox/ﬂox mice. The analysis was extended
to liver-speciﬁc Nf2 knockout mice and Nf2:Amot double knockout
(DKO) mice. These studies established a requirement for Amot in
hepatic ductal cell proliferation and tumor formation in the con-
text of Nf2 loss. In addition, a signiﬁcantly increased expression
of Amot was observed in Nf2-null liver tumors [7].
Interest in Amot’s role in angiogenic-related pathology has re-
vealed several new disease interactions. Angiogenesis is known
to play a pivotal role in age-related macular degeneration, with
VEGF driving neovascularization of the choroid, leading to retina
damage [17,93,94]. VEGF inhibitors are approved for use in macu-
lar degeneration, but with compensatory angiogenic pathways
allowing resistance [95,96], there is signiﬁcant interest in targeting
other drivers of angiogenesis. In a mouse model of macular degen-
eration, intraperitoneal injections of PEGylated Amot Fab reducedchoroidal plaques by 73% [17]. Finally, recent research has corre-
lated Amot expression to microRNA-induced tumor dormancy
[97]. In this disease state, proliferation is balanced by increased
apoptosis and an impairment of angiogenesis. Dormant glioblas-
toma multiforme tumors that expressed dormancy-associated
miRs also showed elevated levels of Amot with enriched angio-
statin, suggesting a potential antiangiogenic mechanism for tumor
dormancy.
Overall, the identiﬁed interactions of Amot within disease path-
ways present a complex picture, with angiogenic signaling and
Hpo–YAP pathway interactions both driving the pathology of a
variety of tumor types. It is clear from the genetic and immuno-
logic studies that Amot is a promising therapeutic target and future
work will undoubtedly reveal a more thorough and cohesive pic-
ture of Amot dysregulation and interactions within a wide range
of tumor and angiogenic disease types.
8. Open questions
There are major gaps in our understanding of the Motin family
of proteins as detailed throughout this review. One of the major
open questions relates to functional redundancy between mem-
bers of the family. While there are clear areas of overlap it is also
clear that there are non-redundant roles that are likely to be cell-
type speciﬁc. Another critical question is which are the relevant
pathways through which the Motins exert their functions. The dis-
covery that the Motins orchestrate the function of multiple signal-
ing pathways, including pathways regulated by small G-proteins
and the Hpo/YAP pathway, draws a complex picture. Interestingly,
the majority of studies examining Amot in animal tumor models
and human tumor samples suggest Amot expression is upregulated
and, in some cases, required for disease progression. This raises
questions regarding which Amot-related pathways are involved
and how these pathways modulate Amot functions within the con-
text of the disease. Again, this is also likely cell-type and context-
dependent. Further complexity has been recently introduced with
the identiﬁcation of post-translational modiﬁcations that likely
regulate the function of the Motin themselves. The role of these
modiﬁcations, as well as other transcriptional and post-transcrip-
tional mechanisms, are only beginning to emerge and ongoing
research by multiple groups will surely lead to a better under-
standing of these mechanisms in short order.
Given the underlying complexity of Motin function, these ques-
tions will be most accurately addressed by employing a combina-
tion of molecular and genetic approaches, in relevant cell types and
whole organism models.
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